News and Trends 5 Jun 2015
NuCana’s potent anti-cancer completed Phase I/II
Good news just keeps on coming from ASCO Annual Meeting. Edinburgh-based NuCana presented in two abstracts the last data from Acelarin, the company’s first anti-cancer agent, produced on its ProTide developing platform. ProTides are NuCana’s new class of anti-cancer agents, which are specifically designed to overcome key cancer resistance mechanisms that severely limit the action […]